Last week, we held an event called “An Evening of Hope” in honor of Rare Disease Day. Speakers included rare disease advocates, researchers, patients, and community members who shared their personal stories, breakthroughs, and messages of hope. #raredisease #patients www.youtube.com/shorts/nGOqc...
At Silicon Slopes, Recursion Chief Business Officer Matt Kinn spoke to Nasdaq’s Kristina Ayanian about Recursion’s differentiated approach and strategic advantages. www.youtube.com/watch?v=JfLA...
Recursion welcomed rare disease advocates, physicians, patients, and community members for “An Evening of Hope” last week in SLC. The event highlighted the critical work happening to raise awareness & accelerate new treatments & best support patients and their families who are waiting for a cure.
Recursion announced yesterday that the company will participate in a number of upcoming investor conferences.
👉 Check out the webcasts at ir.recursion.com.
#investor #financial #AI #drugdiscovery #TechBio
Recursion CSO Dave Hallett was recently appointed as an AI Champion by the UK government. He’s one of 8 AI Champions and will be representing the life sciences industry, helping to inform, guide, and accelerate AI adoption plans in that space.
👉 Learn more: delivery.ai.gov.uk/48/ #TechBio #AI #UK
See you at #SLAS2026! Two of our AI drug discovery experts are presenting at the SLAS International Conference & Exhibition Feb. 7-11 in Boston - on Industrializing Drug Discovery with ML and Leveraging AI to Map Cellular Morphology Across Imaging Modalities. www.slas.org/events-calen...
A new episode of Google’s podcast #WhereTheInternetLives looks at Recursion's approach to making new medicines – relying on massive proprietary datasets spanning biology, chemistry and patient data; supercomputing; and an end-to-end AI platform. www.youtube.com/watch?v=o-8W... #GoogleDataCenters
Leveraging AI & real-world patient data to accelerate drug discovery. In a recent webinar, Sid Jain and Hayley Donnella of Recursion spoke to Shane Woods at Tempus AI about how patient data is driving the latest advances in AI drug discovery. www.tempus.com/resources/co... #TechBio #data 🧪
Beth Bruckheimer, PhD, VP of Clinical Development, shared details on our positive Phase 1b/2 results from the ongoing TUPELO study of REC-4881 for Familial Adenomatous Polyposis (FAP), which offers new hope for patients. www.youtube.com/watch?v=mv0c...
🚀 Recursion has been laying the foundation for a virtual cell from day one – including massive-scale, proprietary biological & chemical datasets, AI models & one of the industry’s most powerful supercomputers. Learn about our progress & what's next: www.recursion.com/news/since-i... #virtualcell
🚀 The energy & momentum happening around life sciences in London – fueled by innovation and investment in #AI – is undeniable, and it was on full display last week at the Jefferies Global Healthcare Conference & London Life Sciences Week presentations and events. www.youtube.com/shorts/r2iwx...
In a new story in Technology Networks, incoming CEO and President Najat Khan shared insights into the creation of the Microglia Map in partnership with Roche and Genentech and what it could mean for future drug discovery. #neuroscience #microglia #TechBio www.technologynetworks.com/drug-discove...
In a new video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts: “What is one thing you wish your families understood about the work that you do?” For many, it’s all about the patients.
#onething #Recursionaut #culture #TechBio #drugdiscovery
www.youtube.com/shorts/ougrI...
Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). Results of the study have been published in the Journal of Bone and Mineral Research.
👉 Read the paper: academic.oup.com/jbmr/advance... #HPP #ENPP1 #TechBio
At the inaugural TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan will present her personal journey merging science and technology to make new medicines and improve the lives of patients. www.ted.com/tedx/events/... #NYC #TED #TEDx
Recursion announced a leadership transition plan to drive the next phase of its growth. Effective Jan. 1st, Chris Gibson, Co-Founder and CEO, will transition to Chairman of the Board, Najat Khan, PhD, Chief R&D and Commercial Officer, will be named CEO and President. ir.recursion.com/news-release...
In our latest Explain the Impact video, we share the inside story of the world's first Microglia Map from Recursion and Roche and Genentech to help unlock new targets in neurodegenerative diseases. #neuroscience #techbio youtube.com/shorts/xvPIQ...
💥 Recursion has achieved a $30 million milestone payment from its partners, Roche and Genentech, following the acceptance of the Microglia Map – a first-of-its-kind whole genome map of the brain’s immune cells.
👉Learn more: www.recursion.com/news/how-a-f... #neuroscience #TechBio
The 3rd episode of TechBio Talks is now live, featuring leading AI investor Nathan Benaich of Air Street Capital with host Chris Gibson discussing the evolving landscape of AI in drug discovery, the biggest trends in Nathan’s new State of AI Report, and more! www.youtube.com/watch?v=MUjT...
What gets you excited?
In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture
www.youtube.com/shorts/zQDQq...
Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."
🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪
Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio
🎙️ Subscribe to TechBio Talks now on:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Apple: podcasts.apple.com/us/podcast/t...
Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.
Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵
👇 Check out TechBio Talks on:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Apple: podcasts.apple.com/us/podcast/t...
or wherever you get your podcasts!
In a clip from our podcast TechBio Talks, MIT's Regina Barzilay tells host Najat Khan how we can leverage machine learning to better predict how a patient will respond to treatments, to improve his or her condition for the “longest time with minimal side effects.” www.youtube.com/shorts/uSEM1... 🧵
Driving this industry-defining innovation takes bold, bilingual thinkers who collaborate across disciplines, and push back against the status quo.
If this sounds like your kind of mission, we're hiring. www.recursion.com/careers
👉See the list: www.fastcompany.com/best-workpla...
We♥️our innovators.
Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.
At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵
